Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2024.07.1491 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treatment of recalcitrant discoid lupus erythematosus with roflumilast 0.3% cream following suboptimal response to anifrolumab and improvement of hypopigmentation.
JAAD Case Rep
December 2024
Department of Dermatology, School of Medicine and Health Sciences, The George Washington University, Washington, District of Columbia.
Anifrolumab in recalcitrant cutaneous dermatomyositis: A multicenter retrospective cohort study.
J Am Acad Dermatol
December 2024
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Dermatology Program, Division of Immunology, Boston Children's Hospital, Boston, Massachusetts.
Rapid Improvement in Recalcitrant Cutaneous Juvenile Dermatomyositis With Anifrolumab Treatment.
JAMA Dermatol
February 2024
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers.
Br J Dermatol
July 2023
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
Background: Observations with rituximab suggest B-cell independent mechanisms of cutaneous lupus erythematosus (CLE) in systemic lupus erythematosus (SLE), especially discoid lupus erythematosus (DLE). Type-I interferon receptor blockade with anifrolumab shows efficacy in SLE, but efficacy for cutaneous disease of specific morphologies has not been studied. Interferon has pleotropic immune effects and it is unknown which of these are critical to therapeutic response.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!